Valuation: Camurus AB

Market Cap 31.33B 3.25B 2.84B 2.63B 2.43B 4.57B 312B 4.65B 12.29B 153B 12.22B 11.95B 527B P/E 2026 *
35.1x
P/E 2027 * 21.9x
Enterprise Value 26.88B 2.79B 2.44B 2.25B 2.08B 3.92B 268B 3.99B 10.55B 131B 10.48B 10.25B 452B EV / Sales 2026 *
9.6x
EV / Sales 2027 * 6.8x
Free-Float
67.52%
Yield 2026 *
-
Yield 2027 * -
1 day-2.48%
Current month-4.10%
1 month+4.48%
3 months-7.57%
6 months+1.14%
Current year-12.83%
1 month 54
Extreme 54
61.01
Current year 54
Extreme 54
71
1 year 54
Extreme 54
71
3 years 46.15
Extreme 46.15
71.07
5 years 21.81
Extreme 21.81
71.07
10 years 7.48
Extreme 7.48
71.07
Manager TitleAgeSince
Chief Executive Officer 63 2002-12-31
Director of Finance/CFO 57 2025-06-30
Chief Tech/Sci/R&D Officer 58 2024-12-31
Director TitleAgeSince
Director/Board Member 69 2024-12-31
Chairman 77 2014-12-31
Director/Board Member 63 2001-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.48%0.00% - - 3.3B
-1.54%-6.53%+44.48%+156.95% 1,054B
-1.22%-5.12%+61.69%+58.60% 621B
-1.47%-3.52%+28.28%+80.64% 438B
-1.12%-3.68%+26.89%+20.58% 325B
-1.73%-3.45%+26.95%+44.09% 281B
-1.95%-13.92%+15.96%+19.76% 262B
-1.45%-2.37%-27.87%-39.87% 219B
-1.69%-3.23%+19.93%+56.63% 195B
-1.24%-4.44%+16.25%+68.82% 163B
Average -1.59%-1.70%+23.62%+51.80% 395.13B
Weighted average by Cap. -1.46%-1.69%+33.31%+77.29%

Financials

2026 *2027 *
Net sales 2.8B 291M 254M 235M 217M 409M 27.92B 416M 1.1B 13.67B 1.09B 1.07B 47.07B 3.76B 391M 341M 316M 292M 549M 37.53B 559M 1.48B 18.38B 1.47B 1.44B 63.28B
Net income 906M 94.02M 82.17M 75.96M 70.18M 132M 9.03B 135M 355M 4.42B 353M 345M 15.23B 1.45B 150M 131M 121M 112M 211M 14.44B 215M 568M 7.07B 565M 552M 24.35B
Net Debt -4.45B -462M -403M -373M -345M -649M -44.35B -661M -1.75B -21.71B -1.73B -1.7B -74.77B -5.74B -595M -520M -481M -444M -837M -57.2B -852M -2.25B -28.01B -2.24B -2.19B -96.43B
Logo Camurus AB
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Employees
308
Date Price Change Volume
26-07-14 US$58.51 -2.48% 100
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
537.50SEK
Average target price
768.12SEK
Spread / Average Target
+42.91%

Quarterly revenue - Rate of surprise